Roche Aims to Deliver 20 New Drugs in Research Overhaul
This article is for subscribers only.
Roche Holding AG is aiming to deliver 20 new medicines to address diseases that rank among the biggest burdens to society this decade, as it seeks to kick-start its development program.
The Swiss drugmaker will target tripling its number of patients between 2020 and 2029, the company said in a presentation posted ahead of an investor meeting in London on Monday. Roche is also seeking to boost its success rate in crucial final-stage clinical trials by about one-fifth, after difficulties clearing that hurdle before drug approvals in recent years.